| Type | Valeur |
|---|---|
| cik | 0000042582 |
| ticker | GT |
Achats discrétionnaires moins ventes en USD par fenêtre roulante. Hors compensation.
| Date | Type | Insider | Quantité | Prix | Signaux |
|---|---|---|---|---|---|
| 15 mai 2026 | EXERCISE | Boucharlat Gregory | 3 170 | 0.00 USD | |
| 15 mai 2026 | TAX_WITHHOLDING | Boucharlat Gregory | 2 111 | 5.64 USD | |
| 15 mai 2026 | EXERCISE | Boucharlat Gregory | 3 170 | 0.00 USD | deriv |
| 15 mai 2026 | EXERCISE | Stewart Mark Wynn | 355 537 | 0.00 USD | |
| 15 mai 2026 | TAX_WITHHOLDING | Stewart Mark Wynn | 163 903 | 5.64 USD | |
| 15 mai 2026 | EXERCISE | Stewart Mark Wynn | 355 537 | 0.00 USD | deriv |
| 01 mars 2026 | EXERCISE | Metzelaar Don | 10 215 | 0.00 USD | |
| 01 mars 2026 | TAX_WITHHOLDING | Metzelaar Don | 3 004 | 8.25 USD | |
| 01 mars 2026 | EXERCISE | Metzelaar Don | 7 150 | 0.00 USD | deriv |
| 01 mars 2026 | EXERCISE | Metzelaar Don | 3 065 | 0.00 USD | deriv |
| 01 mars 2026 | TAX_WITHHOLDING | Madarang Nathaniel | 10 090 | 8.25 USD | |
| 27 févr. 2026 | TAX_WITHHOLDING | Madarang Nathaniel | 13 015 | 8.25 USD | |
| 27 févr. 2026 | EXERCISE | Madarang Nathaniel | 28 921 | 0.00 USD | |
| 01 mars 2026 | EXERCISE | Madarang Nathaniel | 22 419 | 0.00 USD | |
| 27 févr. 2026 | EXERCISE | Madarang Nathaniel | 28 921 | 0.00 USD | deriv |
| 01 mars 2026 | EXERCISE | Madarang Nathaniel | 10 161 | 0.00 USD | deriv |
| 01 mars 2026 | EXERCISE | Madarang Nathaniel | 12 258 | 0.00 USD | deriv |
| 01 mars 2026 | EXERCISE | Snyder Margaret V | 7 984 | 0.00 USD | |
| 01 mars 2026 | TAX_WITHHOLDING | Snyder Margaret V | 3 606 | 8.25 USD | |
| 01 mars 2026 | EXERCISE | Snyder Margaret V | 4 597 | 0.00 USD | deriv |
| 01 mars 2026 | EXERCISE | Snyder Margaret V | 3 387 | 0.00 USD | deriv |
| 01 mars 2026 | TAX_WITHHOLDING | Gray Nicole | 6 840 | 8.25 USD | |
| 01 mars 2026 | EXERCISE | Gray Nicole | 15 080 | 0.00 USD | |
| 01 mars 2026 | EXERCISE | Gray Nicole | 2 822 | 0.00 USD | deriv |
| 01 mars 2026 | EXERCISE | Gray Nicole | 12 258 | 0.00 USD | deriv |